Insurance coverage has expanded for an epigenetic test for prostate cancer and percutaneous tibial nerve stimulation (PTNS) for the treatment of overactive bladder (OAB).
Richard R. Kerr
Contrary to popular belief and scientific predictions, a man’s patency after vasectomy reversal is possible almost 40 years after the original vasectomy, according to a study of more than 1,200 reversals that the authors say is the largest such study ever published.
An investigational minimally invasive device was found safe and effective in limiting rapid pressure changes within the bladder to reduce symptoms of stress urinary incontinence, the authors of a recently published trial reported.
Data are lacking to recommend for or against the use of vitamins, minerals, and multivitamin supplements for the prevention of cancer and cardiovascular disease, according to a new U.S. Preventive Services Task Force draft recommendation statement.
The American College of Surgeons, in collaboration with the AUA and 14 other specialty surgical organizations, has jointly published and released the seventh edition of a report that provides guidance on how often an operation might require the use of a physician as an assistant.
Renacidin Irrigation (Citric Acid, Glucono delta-Lactone, and Magnesium Carbonate) is once again available after a series of manufacturing issues resulted in the product being unavailable for over a year, according to United-Guardian, Inc., the product’s marketer.
Women with common forms of urinary incontinence have various bacteria in their bladder, according to a recent study, and some of these bacteria may differ based on their incontinence type.
While women are far more likely to suffer from urinary tract infections, men are more likely to be hospitalized for treatment, according to a study by urologists from Henry Ford Hospital in Detroit.
In an attempt to clarify what it calls conflicting guideline statements on prostate cancer screening from various organizations, the Large Urology Group Practice Association has issued its own position on the use of the PSA test as a screening tool.
The FDA has authorized the marketing of the UroLift system, the first permanent implant to relieve low or blocked urine flow in men aged 50 years and older with BPH.